FP6Reintegration grant2006–2007

DRUG DELIVERY SYSTEM · Multifunctional Dendrimers as targeted drug delivery systems

FP6 — Marie Curie Actions (Human Resources and Mobility)

Duration
2006-01-01 → 2007-12-31
EU contribution
€80,000
Participants
1
Scheme
IRG

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Results in brief

Final Activity Report Summary - DRUG DELIVERY SYSTEM (Multifunctional Dendrimers as targeted drug delivery systems)

Around the world, one person dies every four seconds due to cancer and related complications. This shocking data urges the scientists to explore new avenues for possible cures. One of the promising areas of research involves targeted drug delivery where the medicine is carried by a vehicle that finds and gets taken up by tumour cells and then kills the cancer. The initial research involves exploration of new vehicles with high carrier capacity which is followed by finding the right combination of the vehicle, drug and the targeting moiety. In this on-going research, we are trying to explore dendrimers as drug delivery agents. The research involves synthesis of novel segment block dendrimers, attachment of the desired drug and targeting groups on these dendrimers and finally their evaluation in vitro as cancer chemotherapy agents. Multifunctional dendrimers have a high potential for drug delivery applications as they accommodate a high density and wide variety of functional groups on their surface. Along with their well-defined molecular structure, segmented spherical construction of dendrimers offers an interesting architecture. While one of these segments is ornamented with active drug molecules, the other one can be decorated with targeting groups. Such a dual design will allow the plasma level of the drug to stay at the desired level for a longer duration, and thus increase its pharmaceutical efficiency. Direct application of drug molecules to the diseased tissue or organ increases the effect of the therapy and decreases the side effects. Therapeutic efficacy of drugs is often diminished due to their low bioavailability, insolubility, toxicity and their decomposition under biological conditions. Conjugating drug molecules onto dendrimers containing targeting moieties can improve all of these shortcomings. The research that started with this project has evolved into three parts: The first part is the synthesis of dendrons (dendrimer pieces) with targeting groups, the second part is the attachment of drug molecules to another dendron and the third and final part is the development of methodology for putting these two pieces together. The most important scientific achievement of the project is the synthesis of bone targeting dendrons and the methodologies developed to successfully join the two pieces to yield dendrimers.

Data: CORDIS, © European Union

Project objective

Multifunctional dendrimers have emerged as potential candidates for targeted drug delivery systems. In the proposed project, dendrons with different surface groups will be synthesized via convergent methodology. New synthetic methods will be developed to obtain dendrimers from combination of such dendrons.Dendrimers having targeting groups and drug moieties conjugated at the surface will be synthesized with the aim of targeted drug delivery to colon and bone. Recently, colon targeting became much more attractive for delivery of drug molecules due to the low digestive enzymatic activity and high residence time compared to the stomach and small intestine. Also, for treatments of local diseases of the colon like ulcerative colitis, Crohn's disease and colon cancer, drug targeting not only reduces the dose to be administered, but also reduces the incidence of possible adverse effects associated with these chemotherapeutic agents. Along with colon targeting, segmented dendrons having bisphosphonate groups, as bone-targeting agents will be synthesized. These multi-functional dendrimers will then be evaluated for their efficiency towards bone adenocarcinoma.

Original text from CORDIS.

Participants

  • BOGAZICI UNIVERSITY · ISTANBULCoordinatorCity levelTürkiye

Links

Data: CORDIS, © European Union